You are here

  • Home
  • Archive
  • Volume 7, Issue 1
  • Antibody targeting tumor-derived soluble NKG2D ligand sMIC provides dual co-stimulation of CD8 T cells and enables sMIC+ tumors respond to PD1/PD-L1 blockade therapy

Article metrics

Article menu

Download PDFPDF

XML
Research Article
Antibody targeting tumor-derived soluble NKG2D ligand sMIC provides dual co-stimulation of CD8 T cells and enables sMIC+ tumors respond to PD1/PD-L1 blockade therapy

 

Online download statistics by month:

Online download statistics by month: December 2019 to July 2025

AbstractFullPdf
Dec 2019880
Jan 202023235
Feb 202025251
Mar 202037373
Apr 202014145
May 202030306
Jun 202018185
Jul 202019194
Aug 2020242210
Sep 2020393915
Oct 2020232312
Nov 2020222213
Dec 2020222210
Jan 202123238
Feb 202117178
Mar 202117179
Apr 2021272713
May 2021242414
Jun 202117179
Jul 202124249
Aug 2021212113
Sep 2021323217
Oct 2021232328
Nov 2021151517
Dec 2021616115
Jan 202224253
Feb 2022373812
Mar 2022696910
Apr 2022353914
May 2022242512
Jun 202220206
Jul 2022434415
Aug 202221236
Sep 2022313212
Oct 2022202619
Nov 2022242621
Dec 202222223
Jan 202322229
Feb 202324248
Mar 202352536
Apr 202316164
May 202322229
Jun 202331316
Jul 202322228
Aug 202321216
Sep 202321215
Oct 202314144
Nov 202310109
Dec 2023313112
Jan 202418189
Feb 2024171711
Mar 2024343412
Apr 2024313210
May 202418184
Jun 202428277
Jul 202430305
Aug 2024141444
Sep 2024181810
Oct 2024292917
Nov 2024131412
Dec 2024394012
Jan 202526269
Feb 202513139
Mar 2025191916
Apr 2025202114
May 2025151511
Jun 2025232511
Jul 2025110
Total16671690691